Your browser doesn't support javascript.
loading
FDA approved vs. Pharmacy compounded 17-OHPC-current issues for obstetricians to consider in reducing recurrent preterm birth.
Gandell, David L; Randell, Michael D; Gudeman, Jennifer L.
Affiliation
  • Gandell DL; Department of Obstetrics and Gynecology, University of Rochester Medical Center, Rochester, NY, USA.
  • Randell MD; OBGYN Atlanta, Emory Saint Joseph's Hospital, Atlanta, GA, USA.
  • Gudeman JL; AMAG Pharmaceuticals, Waltham, MA, USA.
Curr Med Res Opin ; 36(8): 1393-1401, 2020 08.
Article in En | MEDLINE | ID: mdl-32544354
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Approval / Premature Birth / Drug Compounding / 17 alpha-Hydroxyprogesterone Caproate Limits: Female / Humans / Newborn / Pregnancy Country/Region as subject: America do norte Language: En Journal: Curr Med Res Opin Year: 2020 Document type: Article Affiliation country: United States Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Approval / Premature Birth / Drug Compounding / 17 alpha-Hydroxyprogesterone Caproate Limits: Female / Humans / Newborn / Pregnancy Country/Region as subject: America do norte Language: En Journal: Curr Med Res Opin Year: 2020 Document type: Article Affiliation country: United States Country of publication: United kingdom